Stem cell therapy for ischemic heart disease

doi:10.3969/j.issn.2095-4344.2016.06.021

Abstract

Abstract:

BACKGROUND: Stem cell transplantation is a promising strategy for treatment of ischemic heart diseases, which has obtained great achievements in recent years.
OBJECTIVE: To analyze the clinical trends of stem cell therapy for ischemic heart diseases reported from 2001 to 2015 in Medline, CNKI, Wanfang, ClinicalTrials.gov and Chinese Clinical Trial Register.
METHODS: The relevant articles addressing stem cell therapy for ischemic heart diseases were retrieved using the keywords of “stem cell transplantation” and “ischemic heart disease” in Chinese and English in Medline, CNKI, Wanfang, ClinicalTrials.gov and Chinese Clinical Trial Register followed by statistical analysis. The retrieval time was from 2001 to 2015, including 2001-2005, 2006-2010 and 2011-2015.
RESULTS AND CONCLUSION: In Medline database, there were 219 clinical studies about stem cell therapy for ischemic heart disease published from 2001 to 2015, and the number of retrieved articles was most from 2006 to 2010, and decreased from 2011 to 2015. In CNKI and Wanfang databases, the number of relevant articles which had a similar trend with that in the Medline database decreased remarkably after 2011. In ClinicalTrials.gov, there were 63 clinical trials about stem cell therapy for ischemic heart disease, most of which were registered from 2006 to 2015 and came from Europe and North America. In Chinese Clinical Trial Register, there was no clinical trial about stem cell therapy for ischemic heart disease, which may result from the strict management in China.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Miao Lei, Liu Pei-liang. Stem cell therapy for ischemic heart disease[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2016.06.021.

Figures/Tables 5

References

[1] Effat MA. Pathophysiology of ischemic heart disease: an overview. AACN Clin Issues. 1995;6(3):369-374.

[2] Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276- 289.

[3] Reinhardt D, Sigusch HH, Hensse J, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002;88(5): 525-530.

[4] Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. New Engl J Med. 2001;344(23):1750- 1757.

[5] Müller P, Pfeiffer P, Koglin J, et al. Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation. 2002;106(1):31-35.

[6] Kirichenko LL, Iarygina MA, Korolev AP, et al. Assessment of effects of angiotensin converting enzyme inhibitor perindopril on function of endothelium of arterial vessels in patients with ischemic heart disease and hypertension. Kardiologiia. 2004; 44(10): 54-56.

[7] Asakura M, Yamamoto H, Asai K, et al. Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER). Cardiovasc Drugs Ther. 2015;29(2):179-185.

[8] Chang CY, Tsai CS, Peng YJ, et al. Large B-cell lymphoma mimicking ischemic heart disease demonstrated by F-18 fluorodeoxyglucose PET/CT in a heart transplant patient. J. Nucl. Cardiol. 2007;14(5): 754-757.

[9] Ellison Georgina m, Vicinanza C, Smith Andrew j, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repai. Cell. 2013;154(4): 827-842.

[10] Nadal-Ginard B, Ellison GM, Torella D. The cardiac stem cell compartment is indispensable for myocardial cell homeostasis, repair and regeneration in the adult. Stem Cell Research. 2014;13(3 Pt B): 615-630.

[11] Ellison GM, Nadal-Ginard B, Torella D. Optimizing cardiac repair and regeneration through activation of the endogenous cardiac stem cell compartment. J Cardiovasc Transl Res. 2012;5(5):667-677.

[12] Zhao P, Ise H, Hongo M, et al. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation. 2005;79(5):528- 535.

[13] Hattan N, Kawaguchi H, Ando K, et al. Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice. Cardiovasc Res. 2005;65(2):334-344.

[14] Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymal stem cell-derived cardiomyocytes as bio-pacemakers: current status and problems to be solved. Med Biol Eng Comput. 2007;45(2):209-220.

[15] Zhang F, Pasumarthi KB. Embryonic stem cell transplantation: promise and progress in the treatment of heart disease. BioDrugs. 2008;22(6):361-374.

[16] Fukuda K. Progress in myocardial regeneration and cell transplantation. Circ J. 2005;69(12):1431-1446.

[17] Fukuda K, Fujita J. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice. Kidney Int. 2005;68(5):1940-1943.

[18] Fukuda K. Application of mesenchymal stem cells for the regeneration of cardiomyocyte and its use for cell transplantation therapy. Hum Cell. 2003;16(3):83-94.

[19] Ghadge SK, Mühlstedt S, Ozcelik C, et al. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther. 2011;129(1):97-108.

[20] Maslov LN, Podoksenov IuK, Portnichenko AG, et al. Hypoxic preconditioning of stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction. Vestn Ross Akad Med Nauk. 2013;(12):16-25.

[21] Jaerve A, Schira J, Müller HW. Concise review: the potential of stromal cell-derived factor 1 and its receptors to promote stem cell functions in spinal cord repair. Stem Cells Transl Med. 2012;1(10):732-739.

[22] Marquez-Curtis LA, Janowska-Wieczorek A. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis. Biomed Res Int. 2013;2013:561098.

[23] Burlacu A. Tracking the mesenchymal stem cell fate after transplantation into the infarcted myocardium. Curr Stem Cell Res Ther. 2013 Jul;8(4):284-291.

[24] Wang Y, Luther K. Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway. Prog Mol Biol Transl Sci. 2012;111:265-284.

[25] Kwon SM, Lee YK, Yokoyama A, et al. Differential activity of bone marrow hematopoietic stem cell subpopulations for EPC development and ischemic neovascularization. J Mol Cell Cardiol. 2011;51(3): 308-317.

[26] Zisa D, Shabbir A, Suzuki G, et al. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochem. Biophys. Res. Commun. 2009;390(3):834-838.

[27] Deuse T, Peter C, Fedak PW, et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation. 2009;120(11 suppl 1):S247-254.

[28] Pasha Z, Wang Y, Sheikh R, et al. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc. Res. 2008;77(1):134-142.

[29] Strauer BE, Brehm M, Zeus T, et al. Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction. Dtsch Med Wochenschr. 2001;126(34-35): 932-938.

[30] 孙梅,顾健,孙爱红,等.自体外周血干细胞移植治疗糖尿病性下肢动脉闭塞症及缺血性心脏病[J].血栓与止血学, 2006,12(6): 259-261.

[31] 张瑞成,法宪恩,董念国,等.经皮冠状动脉自体骨髓间充质干细胞移植治疗缺血性心力衰竭26例[J].山东医药, 2006, 46(23): 58-59.

[32] 廖德祥,彭枝柳,刘平,等.自体骨髓干细胞移植治疗缺血性心肌病心力衰竭患者近期心功能变化:6个月21例随访[J].中国组织工程研究与临床康复, 2007,11(11):2187-2189.

[33] 王磊,顾健,顾翔,等. APBSCT治疗缺血性心脏病等临床研究[J].血栓与止血学, 2007,13(5):206-208.

[34] 刘平,曾建平,黄河,等.自体骨髓干细胞移植治疗缺血性心肌病的临床研究[J].中国医刊, 2007,42(6):43-44.

[35] 张瑞成,法宪恩,董念国,等.骨髓干细胞移植与冠状动脉腔内支架置入术治疗冠心病疗效对比[J]. 临床心血管病杂志, 2007,23(1):40-42.

[36] 张明,李占全,金元哲,等.自体外周血干细胞经冠状动脉移植治疗急性心肌梗死:近期疗效随访[J].中国组织工程研究与临床康复, 2007,11(20):3944-3947.

[37] 刘盛,胡盛寿,宋云虎,等.冠状动脉旁路移植术同期自体骨髓干细胞移植治疗晚期缺血性心脏病临床研究的早期结果[J].中国循环杂志, 2009,24(4):300-303.

[38] Chugh AR, Beache G, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012; 126(11 Suppl 1):S54-S64.

[39] 张晓霞,王晓曦,段海峰,等.脐带华通胶间充质干细胞治疗缺血性心脏病临床疗效观察[J].军医进修学院学报, 2013, 34(5):431-434.

[40] 杨华强,李红,李玉玲,等.脐血干细胞移植治疗缺血性心脏病的临床研究[J].疑难病杂志, 2014,13(4):361-364.

[41] 李卫东,王玉兵,陈丽,等.脐血干细胞移植治疗缺血性心脏病的临床疗效及安全性分析[J].现代生物医学进展, 2015, 15(24): 4677-4679.

[42] Gao LR, Chen Y, Zhang NK, et al. Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med. 2015;13:162.

[43] Golpanian S, El-Khorazaty J, Mendizabal A, et al. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J Am Coll Cardiol. 2015;65(2):125-132.